$KRON
Kronos Bio, Inc. Stock $kron

$kron Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000174183020000018 Filed on November 18, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.390M	$5.450M	$800.0K
YoY Change	745.95%	581.25%
% of Gross Profit
Research & Development	$11.70M	$16.76M	$3.526M
YoY Change	146.32%	375.18%
% of Gross Profit
Depreciation & Amortization	$800.0K	$200.0K	$100.0K
YoY Change	100.0%	100.0%
% of Gross Profit
Operating Expenses	$21.09M	$20.81M	$4.323M
YoY Change	259.9%	381.36%
Operating Profit		-$20.81M	-$4.323M
YoY Change		381.36%
Interest Expense	-$12.07M	$3.889M	$1.000K
YoY Change	-3194.87%	388800.0%
% of Operating Profit
Other Income/Expense, Net		-$18.90M	$310.0K
YoY Change		-6198.06%
Pretax Income	-$33.16M	-$39.71M	-$4.010M
YoY Change	506.22%	890.27%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$88.44M	-$39.71M	-$4.013M
YoY Change	448.76%	889.61%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.293M	-$3.017M	-$304.7K
COMMON SHARES
Basic Shares Outstanding	56.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$413.1M	$211.3M
YoY Change
Cash & Equivalents	$248.0M	$156.2M	$102.7M
Short-Term Investments	$165.1M	$55.10M
Other Short-Term Assets	$6.100M	$1.400M
YoY Change
Inventory
Prepaid Expenses
Receivables	$600.0K	$200.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$419.8M	$212.9M
YoY Change	349.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.00M	$39.70M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$49.00M	$4.800M
YoY Change
Other Assets	$166.0K	$3.207M
YoY Change	-61.12%
Total Long-Term Assets	$92.16M	$49.66M
YoY Change	882.22%
TOTAL ASSETS
Total Short-Term Assets	$419.8M	$212.9M
Total Long-Term Assets	$92.16M	$49.66M
Total Assets	$512.0M	$262.6M
YoY Change	398.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.550M	$4.443M
YoY Change	202.12%
Accrued Expenses	$4.974M	$1.780M
YoY Change	508.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$173.9M
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$12.86M	$183.6M
YoY Change	376.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.469M	$2.841M
YoY Change	3236.49%
Total Long-Term Liabilities	$2.469M	$2.841M
YoY Change	3236.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.86M	$183.6M
Total Long-Term Liabilities	$2.469M	$2.841M
Total Liabilities	$46.45M	$215.9M
YoY Change	1457.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$111.9M	-$78.75M
YoY Change	376.97%
Common Stock	$54.00K	$6.000K
YoY Change	800.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$465.5M	-$76.28M	-$17.83M
YoY Change
Total Liabilities & Shareholders Equity	$512.0M	$262.6M
YoY Change	398.57%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$88.44M	-$39.71M	-$4.013M
YoY Change	448.76%	889.61%
Depreciation, Depletion And Amortization	$800.0K	$200.0K	$100.0K
YoY Change	100.0%	100.0%
Cash From Operating Activities	-$15.63M	-$10.28M	-$3.490M
YoY Change	216.4%	194.56%
INVESTING ACTIVITIES
Capital Expenditures	-$3.680M	-$4.170M	-$1.460M
YoY Change	475.0%	185.62%
Acquisitions
YoY Change
Other Investing Activities	-$155.1M	-$16.61M	$0.00
YoY Change	139.95%
Cash From Investing Activities	-$158.8M	-$20.78M	-$1.460M
YoY Change	143.24%	1323.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	266.2M	149.3M	50.18M
YoY Change	532300.0%	197.51%
NET CHANGE
Cash From Operating Activities	-15.63M	-10.28M	-3.490M
Cash From Investing Activities	-158.8M	-20.78M	-1.460M
Cash From Financing Activities	266.2M	149.3M	50.18M
Net Change In Cash	91.81M	118.2M	45.23M
YoY Change	-230.86%	161.4%
FREE CASH FLOW
Cash From Operating Activities	-$15.63M	-$10.28M	-$3.490M
Capital Expenditures	-$3.680M	-$4.170M	-$1.460M
Free Cash Flow	-$11.95M	-$6.110M	-$2.030M
YoY Change	177.91%	200.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001741830
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39592
	dei	Entity Registrant Name EntityRegistrantName	Kronos Bio, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1895605
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1300 So. El Camino Real
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Mateo
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94402
	dei	City Area Code CityAreaCode	650
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Local Phone Number LocalPhoneNumber	781-5200
	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	KRON
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56033504	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156196000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32570000	USD
CY2020Q3	us-gaap	Short Term Investments ShortTermInvestments	55069000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	59614000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1628000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1119000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	212893000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	93303000	USD
CY2020Q3	us-gaap	Long Term Investments LongTermInvestments	4774000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	4762000	USD
CY2020Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10301000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3721000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29355000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	473000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3207000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	427000	USD
CY2020Q3	us-gaap	Assets Assets	262556000	USD
CY2019Q4	us-gaap	Assets Assets	102686000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4443000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1506000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1780000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	818000	USD
CY2020Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	173944000	USD
CY2019Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1300000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	285000	USD
CY2020Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2137000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	88000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	183604000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2697000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29484000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	211000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2841000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	74000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	215929000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	2982000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	21506977	shares
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	21506977	shares
CY2020Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	21504893	shares
CY2020Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	21504893	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2020Q3	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	123016000	USD
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	123016000	USD
CY2020Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-76280000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-23203000	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6284326	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6284326	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5660391	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5660391	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2416000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	271000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78749000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23462000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	47000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	262556000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102686000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16755000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3526000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30125000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8698000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4054000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	797000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6831000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2262000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	20809000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	4323000	USD
	us-gaap	Operating Expenses OperatingExpenses	36956000	USD
	us-gaap	Operating Expenses OperatingExpenses	10960000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20809000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4323000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36956000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10960000	USD
CY2020Q3	kron	Notes Payable Fair Value Gain Loss NotesPayableFairValueGainLoss	-15215000	USD
CY2019Q3	kron	Notes Payable Fair Value Gain Loss NotesPayableFairValueGainLoss	0	USD
	kron	Notes Payable Fair Value Gain Loss NotesPayableFairValueGainLoss	-15215000	USD
	kron	Notes Payable Fair Value Gain Loss NotesPayableFairValueGainLoss	0	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	3889000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	1000	USD
	us-gaap	Interest Expense InterestExpense	3890000	USD
	us-gaap	Interest Expense InterestExpense	3000	USD
CY2020Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	200000	USD
CY2019Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	311000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	774000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	311000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18904000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	310000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18331000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	308000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-39713000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4013000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55287000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10652000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-117000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	65000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39830000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4013000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55222000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10652000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.48
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.39
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.05
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6127146	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5409433	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5886191	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5196681	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	7806977	shares
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	17985000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-7296000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3130000	USD
CY2019Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	7806977	shares
CY2019Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	17985000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-10409000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	45000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21000	USD
CY2019Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	7.67
CY2019Q2	kron	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	7142488	shares
CY2019Q2	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	54680000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3509000	USD
CY2019Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	14949465	shares
CY2019Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	72665000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	-13852000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23000	USD
CY2019Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	7.67
CY2019Q3	kron	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	6555428	shares
CY2019Q3	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	50242000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4013000	USD
CY2019Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2019Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	-17831000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-23203000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	188000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	158000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6995000	USD
CY2020Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2020Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-29832000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	113000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	293000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-8579000	USD
CY2020Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2020Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-37981000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	278000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1253000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-117000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-39713000	USD
CY2020Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2020Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-76280000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55287000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10652000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	539000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	215000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-105000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-71000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1734000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	60000	USD
	kron	Lease Expense Noncash LeaseExpenseNoncash	1994000	USD
	kron	Lease Expense Noncash LeaseExpenseNoncash	183000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-15215000	USD
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3889000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3565000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	493000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	271000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-150000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	152000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1129000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	258000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	879000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	434000	USD
	kron	Increase Decrease In Right Of Use Operating Assets And Liabilities Net IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet	588000	USD
	kron	Increase Decrease In Right Of Use Operating Assets And Liabilities Net IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet	183000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	4816000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-32000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22282000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10140000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5886000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2311000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	41205000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	45611000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1480000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2311000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	24000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	22000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	411000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	104929000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	151275000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2248000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	149414000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	104963000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	125652000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	92512000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32570000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10226000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158222000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102738000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1325000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	478000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	30898000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	kron	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	682000	USD
	kron	Deferred Offering Costs Incurred But Not Yet Paid DeferredOfferingCostsIncurredButNotYetPaid	0	USD
	kron	Temporary Equity Issuance Costs Incurred But Not Yet Paid TemporaryEquityIssuanceCostsIncurredButNotYetPaid	0	USD
	kron	Temporary Equity Issuance Costs Incurred But Not Yet Paid TemporaryEquityIssuanceCostsIncurredButNotYetPaid	8000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2900000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-78700000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. </span></div>Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of convertible notes and investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets.
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2000000.0	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and investments. The primary objectives for the Company’s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the FDIC and concentrated within a limited number of financial institutions. The accounts are monitored by management and management believes that the financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these financial institutions. As of September 30, 2020 and December 31, 2019, the Company has not experienced any credit losses in such accounts or investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks common for biopharmaceutical companies, including, but not limited to, dependency on the clinical and commercial success of its product candidates, ability to obtain regulatory approval of its product candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition, and untested manufacturing capabilities.</span></div>
CY2020Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	2900000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156196000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102738000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158222000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102738000	USD
CY2020Q3	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost	144769000	USD
CY2020Q3	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax	57000	USD
CY2020Q3	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax	10000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	144816000	USD
CY2019Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost	71145000	USD
CY2019Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax	2000	USD
CY2019Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax	20000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	71127000	USD
	kron	Debt Securities Available For Sale Remaining Contractual Maturity DebtSecuritiesAvailableForSaleRemainingContractualMaturity	P23M
CY2020Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	84973000	USD
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6751000	USD
CY2020Q3	us-gaap	Short Term Investments ShortTermInvestments	55069000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	59614000	USD
CY2020Q3	us-gaap	Long Term Investments LongTermInvestments	4774000	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	4762000	USD
CY2020Q3	us-gaap	Investments And Cash InvestmentsAndCash	144816000	USD
CY2019Q4	us-gaap	Investments And Cash InvestmentsAndCash	71127000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	55407000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	66253000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	4774000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	4762000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	84635000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	112000	USD
CY2020Q3	us-gaap	Investments And Cash InvestmentsAndCash	144816000	USD
CY2019Q4	us-gaap	Investments And Cash InvestmentsAndCash	71127000	USD
CY2019	kron	Debt Securities Available For Sale Remaining Contractual Maturity DebtSecuritiesAvailableForSaleRemainingContractualMaturity	P18M
CY2020Q3	kron	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	217000	USD
CY2019Q4	kron	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	198000	USD
CY2020Q3	kron	Prepaid Equipment Service Contracts PrepaidEquipmentServiceContracts	432000	USD
CY2019Q4	kron	Prepaid Equipment Service Contracts PrepaidEquipmentServiceContracts	191000	USD
CY2020Q3	kron	Prepaid External Research And Development PrepaidExternalResearchAndDevelopment	410000	USD
CY2019Q4	kron	Prepaid External Research And Development PrepaidExternalResearchAndDevelopment	113000	USD
CY2020Q3	kron	Prepaid Software PrepaidSoftware	254000	USD
CY2019Q4	kron	Prepaid Software PrepaidSoftware	180000	USD
CY2020Q3	us-gaap	Prepaid Insurance PrepaidInsurance	36000	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	23000	USD
CY2020Q3	us-gaap	Prepaid Rent PrepaidRent	3000	USD
CY2019Q4	us-gaap	Prepaid Rent PrepaidRent	196000	USD
CY2020Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	276000	USD
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	218000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1628000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1119000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	139000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	139000	USD
CY2020Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	11286000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	4167000	USD
CY2020Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	985000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	446000	USD
CY2020Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	10301000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3721000	USD
CY2020Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1107000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	528000	USD
CY2020Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	38000	USD
CY2019Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	43000	USD
CY2020Q3	kron	Accrued External Research And Development Current AccruedExternalResearchAndDevelopmentCurrent	469000	USD
CY2019Q4	kron	Accrued External Research And Development Current AccruedExternalResearchAndDevelopmentCurrent	241000	USD
CY2020Q3	kron	Accrued Offering Costs Current AccruedOfferingCostsCurrent	83000	USD
CY2019Q4	kron	Accrued Offering Costs Current AccruedOfferingCostsCurrent	0	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	83000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1780000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	818000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	14000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	32000	USD
CY2020Q3	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2123000	USD
CY2019Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	56000	USD
CY2020Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2137000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	88000	USD
CY2020Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	21506977	shares
CY2020Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	21504893	shares
CY2020Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2020Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2020Q3	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	123016000	USD
CY2020Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22687625	shares
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	21506977	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	21504893	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	21504893	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	122907000	USD
CY2019Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	123016000	USD
CY2019Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22687625	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6284326	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6284326	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5660391	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5660391	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.66
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.54
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.16
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.88
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.69
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.09
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1726233	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.19
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y18D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	27287000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4015631	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.70
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	117921	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.76
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	406057	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.01
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5217886	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.91
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M2D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	68291000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	69910	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.33
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y5M4D
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1096000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5147976	shares
	kron	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares	1551361	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.95
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y4M9D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	67195000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1500000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000.0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1253000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1734000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60000	USD
CY2020Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14100000	USD
CY2020Q3	kron	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares	850937	shares
CY2019Q3	kron	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares	60924	shares
	kron	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseShares	60924	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-39713000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4013000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-55287000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10652000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6127146	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5409433	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5886191	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5196681	shares
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.48
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.39
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.05
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39129352	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24172957000	shares
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	88000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	103000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	14000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	32000	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	5000	USD
CY2020Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	14000	USD
CY2019Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	37000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29355000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	473000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1300000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	285000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29484000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	211000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	30784000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	496000	USD
CY2020Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2019Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5000	USD
CY2019Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	6000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	16000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	18000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1785000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	78000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3733000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	233000	USD
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	700000	USD
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	200000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1329000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5770000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4789000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4933000	USD
CY2020Q3	kron	Lessee Operating Lease Liability To Be Paid Year Four And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter	35915000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	52736000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18238000	USD
CY2020Q3	us-gaap	Tenant Improvements TenantImprovements	3714000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	30784000	USD
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares

Files In Submission

Name	View Source	Status
0001741830-20-000018-index-headers.html	Edgar Link	pending
0001741830-20-000018-index.html	Edgar Link	pending
0001741830-20-000018.txt	Edgar Link	pending
0001741830-20-000018-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kron-20200930.htm	Edgar Link	pending
kron-20200930.xsd	Edgar Link	pending
kron-20200930_cal.xml	Edgar Link	unprocessable
kron-20200930_def.xml	Edgar Link	unprocessable
kron-20200930_htm.xml	Edgar Link	completed
kron-20200930_lab.xml	Edgar Link	unprocessable
kron-20200930_pre.xml	Edgar Link	unprocessable
kronq3fy2020ex101.htm	Edgar Link	pending
kronq3fy2020ex311.htm	Edgar Link	pending
kronq3fy2020ex312.htm	Edgar Link	pending
kronq3fy2020ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRON
Kronos Bio, Inc. Stock $kron

2020 Q4 Form 10-Q Financial Statement

#000174183020000018 Filed on November 18, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRON Kronos Bio, Inc. Stock $kron

2020 Q4 Form 10-Q Financial Statement

#000174183020000018 Filed on November 18, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRON
Kronos Bio, Inc. Stock $kron